2023
Hydroxychloroquine in Stage 1 Type 1 Diabetes.
Libman I, Bingley P, Becker D, Buckner J, DiMeglio L, Gitelman S, Greenbaum C, Haller M, Ismail H, Krischer J, Moore W, Moran A, Muir A, Raman V, Steck A, Toledo F, Wentworth J, Wherrett D, White P, You L, Herold K, Steck A, Greenbaum C, Lord S, Monzavi R, Katz L, Goland R, Muir A, Apperson E, DiMeglio L, Cummings E, Weinstock R, Gaglia J, Campbell F, Cabrera S, Nakhle S, English P, Huynh T, Liljenquist D, Moudiotis C, Duke S, Bosi E, Griffin K, Borg H, Lernmark A, Flynn D, Wilson D, Craig M, Moore W, Wherrett D, Tatovich D, Gitelman S, Philipson L, Haller M, Knip M, Tsalikian E, Baidal D, Thomas I, Moran A, Libman I, White P, Raman V, Raleigh Z, Solorzano C, Rodriguez H, Russell W, So M, Colman P, Couper J, Sherr J. Hydroxychloroquine in Stage 1 Type 1 Diabetes. Diabetes Care 2023, 46: 2035-2043. PMID: 37708415, PMCID: PMC10620539, DOI: 10.2337/dc23-1096.Peer-Reviewed Original ResearchConceptsAnnual ophthalmologic examinationsMedian follow-upStage 1 diseaseHydroxychloroquine armPreplanned secondary analysisAutoantibodies to GADData Safety Monitoring BoardAnti-insulin autoantibodiesSafety monitoring boardType 1 diabetesInnate immune responseOphthalmologic examinationPositive autoantibodiesAnti-GADHydroxychloroquine treatmentMonth 6Oral glucoseFollow-upDrug treatmentImmune responseHydroxychloroquineAutoantibodiesTransient decreaseMonitoring boardReduced titers
2018
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes 2018, 67: dbi180002. PMID: 29937434, PMCID: PMC6054443, DOI: 10.2337/dbi18-0002.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Agents, ImmunologicalAutoimmune DiseasesB7-H1 AntigenDiabetes Mellitus, Type 1Genetic Predisposition to DiseaseGenotypeHLA-DR4 AntigenHumansHypoglycemic AgentsInsulinInsulin SecretionIsoantibodiesKetosisModels, ImmunologicalNeoplasmsPancreasPancreatitisProgrammed Cell Death 1 ReceptorConceptsInsulin-dependent diabetesCheckpoint inhibitorsAdverse eventsHLA-DR4Classic type 1 diabetesPD-L1 checkpoint inhibitorsEvidence of pancreatitisImmune adverse eventsSolid organ cancersType 1 diabetesPeridiagnosis periodPositive autoantibodiesL1 antibodyInsulin-DependentHigh riskPatientsDiabetesCancerInhibitorsKetoacidosisAutoimmuneAutoantibodiesPancreatitisComplicationsSyndrome
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply